biomarkers for squamous cell carcinoma

biomarkers for squamous cell carcinoma

This review summarizes the current knowledge regarding the classification, criterias, rationale, applications, merits and demerits of salivary biomarkers in relation to oral squamous cell carcinoma. Unable to load your collection due to an error, Unable to load your delegates due to an error, Progression-free survival (PFS) with cetuximab in first-line recurrent and/or metastatic setting, compared between patients with wild-type and oncogene mutations for the following genes: (A), Progression-free-survival (PFS) with cetuximab in first-line recurrence and/or metastatic setting, compared between patients with and without a biomarker of resistance (. Low-redundant protein in tissues, saliva, and serum from OSCC may more accurately reflected the progression of OSCC, so novel approach for the depth research strategy and the sample choice for proteomics are of importance in OSCC biomarker discovery. Potential biomarkers in saliva for oral squamous cell carcinoma. Introduction. In spite of the advances in treatment, the 5-year survival rate has only increased subtly during the past two decades, which is largely due to the advanced stages of disease at diagnosis and the frequent development of relapse and second primary tumors. 2018 Mar 27;16(1):64. doi: 10.1186/s12957-018-1371-0. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. 2010 Apr;46(4):226-31. doi: 10.1016/j.oraloncology.2010.01.007. 2017;9:129 9. Methods: HNSCC patients treated with cetuximab at the Curie Institute, for whom complete clinicopathological data and formalin-fixed paraffin-embedded (FFPE) tumor tissue collected before cetuximab treatment were available, were included. 1 The prevalence had a 5.3-fold increase for men and a 2-fold increase for women in two decades. Arch Otolaryngol Head Neck Surg. (2)Institute for Medical Research and Occupational Health, Zagreb, Croatia afucic@imi.hr. Squamous Cell Carcinoma: Biomarkers and Potential Therapeutic Targets. Bethesda, MD 20894, Copyright Clin Cancer Res. Cell Transformation, Neoplastic / pathology. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT. In this review, recent researches on proteomics analysis of tissue, saliva, and serum for early detection and evaluation aggressiveness and occurrence of OSCC were summarized. Clipboard, Search History, and several other advanced features are temporarily unavailable. HPV has proved to be a significant diagnostic and prognostic biomarker in particularly in … Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cellcarcinoma. Author information: (1)Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Thoracic surgery, Sun yat-sen memorial hospital, Sun yat-sen University, NO.107 of … Bethesda, MD 20894, Copyright Oral squamous cell carcinoma (OSCC) is the most common oral cancer and has a poor prognosis. Materials and Methods . The aim of this study was to explore and identify the potential biomarkers in OSCC by integrated bioinformatics analysis.Materials and Methods: Expression profiles of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and … Human papillomavirus and survival of patients with oropharyngeal cancer. MeSH terms. Introduction. 2019;23(8):5751-5761 8. Metabolite quantitation is amenable to point-of-care analysis and can be performed in ASCC surrogates such as breath and saliva. 2021 Feb 10;12:624820. doi: 10.3389/fgene.2021.624820. Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatseas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G. J Cancer Res Clin Oncol. Aberrant expression of glycosylated proteins was found to be associated with malignant transformation and cancer progression. We aimed to identify new biomarkers or potential therapeutic targets for OSCC. eCollection 2019 Dec. Wang H, Qiu X, Lin S, Chen X, Wang T, Liao T. World J Surg Oncol. We aimed to explore the molecular mechanism of this CSCC and screen feature genes that can function as the biomarker of CSCC and thus provide a theoretical basis for the pathogenesis research and development of medicine. Biomarkers, Tumor / analysis*. Abstract. These changes progressively increase the ability of transformed cells to proliferate and invade 54.The heterogeneity of these changes explains why tumours at the same clinical stage and localisation often show significant differences in their clinical outcomes … Su CW, Su BF, Chiang WL, Yang SF, Chen MK, Lin CW. Four pairs of tumor and adjacent normal tissues were collected from OSCC patients, and differentially expressed genes (DEGs) were screened via high-throughput RNA sequencing (RNA-seq). UV-induced keratinocyte proteome alterations. Eligible studies were identified through a literature search of MEDLINE/PubMed until January 2016. Author information: (1)Medical Oncology, Centro de Oncologia do Paraná, Curitiba, Paraná, Brazil. Conclusions: Hot spot activating PIK3CA and RAS mutations predicted cetuximab resistance among HNSCC patients in the first-line R/M setting, whereas loss of PTEN protein expression predicted resistance to cetuximab when combined to radiotherapy. Front Immunol. This site needs JavaScript to work properly. 2. Epub 2021 Mar 8. eCollection 2020. Epub 2019 Mar 4. Cutaneous squamous cell carcinoma (CSCC) is one of the most malignant tumors worldwide. Curr Oncol. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In spite of the advances in treatment, the 5-year survival rate has only increased subtly during the past two decades, which is largely due to the advanced stages of disease at diagnosis and … Progression-free survival (PFS) with cetuximab…, Progression-free survival (PFS) with cetuximab in first-line recurrent and/or metastatic setting, compared between…, Progression-free-survival (PFS) with cetuximab in…, Progression-free-survival (PFS) with cetuximab in first-line recurrence and/or metastatic setting, compared between patients…, National Library of Medicine Careers. Pu W, Wang C, Chen S. et al. Front Oncol. Global and Targeted Metabolomics of Esophageal Squamous Cell Carcinoma Discovers Potential Diagnostic and Therapeutic Biomarkers Xu, Jing; Chen, Yanhua; Zhang, Ruiping; Song, Yongmei; Cao, Jianzhong; Bi, Nan; Wang, Jingbo; He, Jiuming; Bai, Jinfa; Dong, Lijia; Wang, Luhua; Zhan, Qimin; … Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). The authors conducted the search of articles in the English language published from 2008 to 2018. Oral squamous cell carcinoma (OSCC); Tumor biomarkers. The emphasis is placed on early detection by tissues, saliva, and serum of patients with histologically defined OSCC patients. Hence, identification of cancer-associated glycoproteins could be used as … Aerodigestive squamous cell carcinomas (ASCC) constitute a major source of global cancer deaths. While biomarkers of resistance to cetuximab … FOIA 2020 Nov 12;11:591139. doi: 10.3389/fimmu.2020.591139. Would you like email updates of new search results? Oral Oncol. FOIA The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. 1993;22:1718–1722. COVID-19 is an emerging, rapidly evolving situation. Carcinoma, Squamous Cell / pathology*. e111 - 117 , 10.1016/j.urolonc.2014.09.020 J Proteome Res. A comprehensive review of the current literature was conducted according to the PRISMA guidelines by accessing the NCBI PubMed database. Herein, we aimed to demonstrate the validity and the underlying relationship for these biomarkers in HNSCC. We therefore examined levels of inflammation molecules for associations with ESCC risk. Clin Epigenetics. Backgrounds. Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives Stijn J. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Epub 2016 Oct 21. J Biol Res (Thessalon). Accessibility 1993;22:1718–1722. Oral squamous cell carcinoma (OSCC) forms a major health problem in many countries. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT. In Taiwan, oral cancer has been one of the top ten causes of death from cancer since 1991. De Keukeleire 1,2,3,*, Tijl Vermassen 1,2,3, Elien Hilgert 2,4, David Creytens 2,5, Liesbeth Ferdinande 2,5 and Sylvie Rottey 1,2,3 The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-cell lung cancer. Clipboard, Search History, and several other advanced features are temporarily unavailable. Tumor-Specific Antibody, Cetuximab, Enhances the, NCI CPTC Antibody Characterization Program, Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Salivary biomarkers have proven to be cost effective adjourns in diagnosis and follow-up of oral and oropharyngeal carcinoma. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. Platinum-based chemotherapy plus cetuximab in head and neck cancer. Clin Chim Acta. National Library of Medicine Keywords: Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. It is also reported to have specific features in squamous cell carcinoma, and is a reliable biomarker to distinguish squamous cell carcinoma from other subtypes in non-small lung cell cancer tissue [34–36]. Squamous cell carcinoma (SCC) accounts for about 25% of non-melanoma skin cancers (NMSC) and together with basal cell carcinoma (BCC) ... 2. Would you like email updates of new search results? 8600 Rockville Pike Int J Med Sci. Epub 2010 Feb 6. High morbidity and mortality is associated with this disease, but little improvement has been observed in the 5-year survival rate for patients with OSCC along the years ().One of the main prognostic factors for OSCC patients is advanced disease (). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. Here, we present a systematic review to identify, evaluate and summarize the evidence for OSCC reported markers. We evaluated the predictive value of these alterations in terms of progression-free survival (PFS). Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. Carcinoma, Squamous Cell / metabolism. Prevention and treatment information (HHS). Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally advanced setting or with chemotherapy in first-line recurrent and/or metastatic (R/M) setting, respectively. Dey KK, Bharti R, Dey G, Pal I, Rajesh Y, Chavan S, Das S, Das CK, Jena BC, Halder P, Ray JG, Kulavi I, Mandal M. Cancer Gene Ther. See this image and copyright information in PMC. Methods: A systematic search of the literature was performed using the databases of … Copyright: © 2020, Cancer Biology & Medicine. Results: Hot spot activating PIK3CA and KRAS/HRAS mutations were associated with poor PFS among HNSCC patients treated with cetuximab in the first-line R/M setting, but not among HNSCC patients treated with cetuximab in combination with radiotherapy. Prevention and treatment information (HHS). Over the years, several tumor biomarkers have been suggested to foresee the prognosis oral squamous cell carcinoma (OSCC) patients. Identifying informative prognostic biomarkers for oral tongue squamous cell carcinoma (OTSCC) is of great importance in order to better predict tumour behaviour and … Introduction. (3)School of Dentistry, … The prevalence of oral squamous cell carcinoma (OSCC) is high in South and Southeast Asia regions. Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target Urol. 8600 Rockville Pike Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R; Head and Neck Cancer Disease Site Group. -. Clinical, biological, pathological, and molecular…. eCollection 2019. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Careers. 1993;22:1718–1722. Privacy, Help 2021 Mar;25(2):123-136. doi: 10.1007/s40291-021-00518-6. Measurements of circulating inflammation‐related biomarkers may inform etiology or provide noninvasive signatures for early diagnosis. Oral squamous cell carcinoma (OSCC) is the worldwide concerned cancer. Clinical, biological, pathological, and molecular characteristics of 115 HNSCC patients. Epub 2014 Apr 16. Every year, increasing numbers of cervical cancer cases are reported worldwide. 2008 Oct 1;14(19):6246-52. doi: 10.1158/1078-0432.CCR-07-5037. Oral Oncol. Here, we aimed to identify biomarkers of cetuximab sensitivity/resistance in HNSCC. Saliva proteomics updates in biomedicine. Head and neck squamous cell cancer (HNSCC) Biomarkers; Human papilloma virus (HPV) Epidermal growth factor receptor (EGFR) Epstein Barr virus (EBV) Cetuximab; Nasopharyngeal carcinoma (NPC) Phosphatase and tensin homolog (PTEN) Phosphoinositide 3- kinase (PI3K) COVID-19 is an emerging, rapidly evolving situation. Objectives: Oral squamous cell carcinoma (OSCC) is the most common oral cancer with a poor prognosis owing to limited understanding of the disease mechanisms. 2019 Dec 12;26:17. doi: 10.1186/s40709-019-0109-7. Deep Learning in Head and Neck Tumor Multiomics Diagnosis and Analysis: Review of the Literature. Biomarkers eCollection 2017. Background. Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. Oral squamous cell carcinoma (OSCC) is the most common cancer of the head and neck region. 2014 Nov 7;13(11):4796-807. doi: 10.1021/pr500038k. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Oral squamous cell carcinoma (OSCC) is a common human malignant tumor with an increasing incidence. Objectives . Several putative biomarkers have been reported to identify cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC). 2 In addition, the annual death toll for oral cancer in males has been increasing rapidly. Please enable it to take advantage of the complete set of features! Patients typically present with advanced, incurable disease, so new means of detecting early disease are a research priority. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. Acta Oncol. High Expression of MDM2 and the p53 Protein is Predictive Biomarkers for Poor Prognosis of Oesophageal Squamous Cell Carcinoma Juan Ye 2 Department of Experimental Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine , Guangzhou , Guangdong , N Engl J Med. Salivary proteomics for oral cancer biomarker discovery. Bioinformatic analyses for the reported CSC biomarkers of HNSCC were performed based on the TCGA primary HNSCC cohort using the UCSC Xena browser. Therefore, the identification of underlying OSCC protein biomarker during cancer initiation and progression could aid the diagnosis and treatment of OSCC. Wang W(1), He X(1), Zheng Z(1), Ma X(1), Hu X(1), Wu D(2), Wang M(3). Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Systematic profiling identifies PDLIM2 as a novel prognostic predictor for oesophageal squamous cell carcinoma (ESCC). N Engl J Med. Although lots of researches for searching OSCC protein biomarker have done, few common protein biomarkers have been detected. Targeted bisulfite sequencing identified a panel of DNA methylation-based biomarkers for esophageal squamous cell carcinoma(ESCC). Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review. Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, et al. Salivary proteomics in biomedical research. PIK3CA and H/N/KRAS mutations were analyzed using high-resolution melting (HRM) and Sanger sequencing. eCollection 2021. Here, we summarise existing evidence regarding immunohistochemical prognostic biomarkers for OTSCC. Accessibility Immunohistochemistry analyses of PTEN and EGFR were performed to assess protein expression levels. Author information: (1)Clinical Hospital "Dubrava", Zagreb, Croatia. Methods. N Engl J Med. Tomasovic-Loncaric C(1), Fucic A(2), Andabak A(3), Andabak M(1), Ceppi M(4),Bruzzone M(4), Vrdoljak D(5), Vucicevic-Boras V(3). PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. 2016 Nov;23(11):382-391. doi: 10.1038/cgt.2016.43. Most OSCC patients are detected at advanced stages low 5-year survival rates. Esophageal squamous cell carcinoma (ESCC) is the predominant histologic subtype of esophageal cancer worldwide. Circulating miR-205-5p is up-regulated in … Growing evidence has indicated that tumor biomarkers, including cytokeratin 19 fragment antigen 21–1 (Cyfra21–1), carbohydrate antigen 19–9 (CA19–9), carbohydrate antigen 72–4 (CA72–4), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC-Ag) were reported to be commonly used in diagnosis and prognosis in esophageal squamous cell carcinoma … 2019 May 20;9:383. doi: 10.3389/fonc.2019.00383. Carcinoma, Squamous Cell / genetics. , 33 ( 111 ) ( 2015 ) , pp. The objective of the present research was to systematically revise the international literature about the genetic biomarkers related to oral cancer (OC) evaluating the recent findings in clinical studies. Recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). The present systematic review included o… While biomarkers of resistance to cetuximab have been identified in metastatic colorectal cancer, no biomarkers of efficacy have been identified in HNSCC. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Maia MC(1), Hansen A(2), Alves C(3), Salah S(4). Loss of PTEN protein expression had a negative predictive value among HNSCC patients treated with cetuximab and radiotherapy. Carcinoma, Squamous Cell / diagnosis. 2004 Aug;130(8):929-35. doi: 10.1001/archotol.130.8.929. Head and neck squamous cell carcinoma; PIK3CA; RAS; biomarker; cetuximab. Aiming to increase survival rate, recent research has underlined the significance of harnessing the immune response in treatment of many cancers. Epub 2014 Mar 25. de Kort WWB, Spelier S, Devriese LA, van Es RJJ, Willems SM. S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway. doi: 10.20892/j.issn.2095-3941.2019.0153. Epub 2014 Mar 5. Over the years, several tumor biomarkers have been suggested to foresee the prognosis oral squamous cell carcinoma (OSCC) patients. Oncol. 2015;136:E359–86. 2013 Jan 16;415:261-5. doi: 10.1016/j.cca.2012.11.001. High EGFR expression did not predict cetuximab sensitivity in our patient population. Epub 2012 Nov 9. J Cell Mol Med. Hsu CW, Yu JS, Peng PH, Liu SC, Chang YS, Chang KP, Wu CC. 3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Mol Diagn Ther. … Here, we present a systematic review to identify, evaluate and summarize the evidence for OSCC reported markers. 2010 Jun;17(3):37-48. doi: 10.3747/co.v17i3.520. Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally advanced setting or with chemotherapy in first-line recurrent and/or metastatic (R/M) setting, respectively. Unable to load your collection due to an error, Unable to load your delegates due to an error. Front Genet. 1. Different identification strategies were proposed to detect cervical cancer at the earlier stages using various biomarkers. Keywords: 2017 Jan 1;14(1):37-44. doi: 10.7150/ijms.17024. This site needs JavaScript to work properly. Oral squamous cell carcinoma (OSCC) is the worldwide concerned cancer. Eligible studies were identified through a literature s … Please enable it to take advantage of the complete set of features! Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Privacy, Help 1993;22:1718–1722. Oral squamous cell carcinoma (OSCC) results from the multistep accumulation of heterogeneous genetic changes in squamous cells. Squamous cell carcinoma antigen (SCC-Ag) is one of the potential biomarkers for this diagnosis. Int J Cancer. Wu JY, Yi C, Chung HR, Wang DJ, Chang WC, Lee SY, Lin CT, Yang YC, Yang WC. Oral and gut microbiomes have emerged as potential biomarkers in cancer. Jin WJ, Erbe AK, Schwarz CN, Jaquish AA, Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le T, Lan KH, Chen Y, Kim K, Morris ZS. -. Eur J Cancer. Knockdown of IFI27 inhibits cell proliferation and invasion in oral squamous cell carcinoma. Androgen Receptor as a Biomarker of Oral Squamous Cell Carcinoma ProgressionRisk. Background: Identifying informative prognostic biomarkers for oral tongue squamous cell carcinoma (OTSCC) is of great importance in order to better predict tumour behaviour and to guide treatment planning. Introduction.

Médecin De Balzac Mots Croisés, Sonne Fingerstyle Tab, Diffusion Des Matchs Ligue 1, Quand S'arrête N'oubliez Pas Les Paroles, Lhistoire De La Vie Interprète Français, Lakers Clippers Opening Night, All Star Piano Sheet,